חיסון לנגיף הפפילומה האנושי
לקריאה נוספת

The FUTURE II Study Group. Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions. The NEJM, 10, 356, 19, 2007.
Suzanne M. G., Mauricio H.A., Cosette M. W..Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases. The NEJM. 10, 356,19,2007.
Dominiak-Felden G, Gobbo C, Simondon F. Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study. PLoS One. l 6;10. eCollection 2015.
Barbaro B., Brotherton JM., Measuring HPV vaccination coverage in Australia: comparing two alternative population-based denominators. Aust N Z J Public Health. Jun 11, 2015.
No author listed. Efficacy HPV in late 2014. Prescrire Int. May;24(160):126-7, 2015.
Shavit O, Roura E, Barchana M, Diaz M, Bornstein J. Burden of Human Papillomavirus Infection and related diseases in Israel. Vaccine, 31S8, 132, 2013.
Chido-Amajuoyi OG, Domgue JF, Obi-Jeff C. A call for the introduction of gender-neutral HPV vaccination to national immunisation programmes in Africa. The Lancet Global Health 2019;7(1):E20-E21. doi: 10.1016/S2214-109X(18)30405-4.
International Agency for Research on Cancer (IARC)’s Monographs on the identification of carcinogenic hazards to humans. List of classified agents, Volumes 1-125: https://monographs.iarc.fr/agents-classified-by-the-iarc/ (accessed 22 June 2020).
Kombe Kombe AJ, Li B, Zahid A, Mengist HM, Bounda GA, Zhou Y, Jin T. Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation. Front Public Health. 2021 Jan 20;8:552028. doi: 10.3389/fpubh.2020.552028. PMID 33553082; PMCID: PMC7855977.
Van Dyne EA, Henley SJ, Saraiya M, et al. Trends in Human Papillomavirus–Associated Cancers — United States, 1999–2015. Morbidity and Mortality Weekly Report 2018;67:918–924. doi: 10.15585/mmwr.mm6733a2
San Giorgi MRM, Aaltonen LM, Rihkanen H, et al. Quality of life of patients with recurrent respiratory papillomatosis. Laryngoscope 2017;127(8):1826-1831. doi:10.1002/lary.26413.
Vesikari T et al., A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9–15-Year-Old Girls, The Pediatric Infectious Disease Journal, 2015 34(9):992-8. doi: 10.1097/INF.0000000000000773.
Jaime Restrepo, Teobaldo Herrera, Rudiwilai Samakoses, Julio C. Reina, Punnee Pitisuttithum, Angels Ulied, Linda-Gail Bekker, Edson D. Moreira, Sven-Eric Olsson, Stan L. Block, Luciano S. Hammes, Fabio Laginha, Alex Ferenczy, Robert Kurman, Brigitte M. Ronnett, Mark Stoler, Oliver Bautista, Nancy E. Gallagher, Gino Salituro, Min Ye, Alain Luxembourg; Ten-Year Follow-up of 9-Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and Safety. Pediatrics October 2023; 152 (4): e2022060993. 10.1542/peds.2022-060993
Huh et al., Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial, Lancet, 2017 11;390(10108):2143-2159. doi: 10.1016/S0140-6736(17)31821-4. Epub 2017 Sep 5.
Reuschenbach M, Doorbar J, Del Pino M, Joura EA, Walker C, Drury R, Rauscher A, Saah AJ. Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer. Vaccine. 2023 Sep 11:S0264-410X(23)00990-8. doi: 10.1016/j.vaccine.2023.08.047.
Meites E, Szilagyi PG, Chesson HW, et al. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report 2019;68:698–702. doi: 10.15585/mmwr.mm6832a3.
Nätverket Mot Gynekologisk Cancer. A Sweden free from cervical cancer. https://www.gyncancer.se/utrotalivmo-derhalscancer/ (accessed 9 July 2020).
Bruni L, Albero G, Rowley J, Alemany L, Arbyn M, Giuliano AR, Markowitz LE, Broutet N, Taylor M. Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis. Lancet Glob Health. 2023 Sep;11(9):e1345-e1362. doi: 10.1016/S2214-109X(23)00305-4. PMID 37591583; PMCID: PMC10447222.
Joint Committee on Vaccination and Immunisation (2018). Statement on HPV vaccination. https://assets.pub-lishing.service.gov.uk/government/uploads/system/uploads/ attachment_data/file/726319/JCVI_Statement_on_HPV_vaccination_2018.pdf